Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery

Background: The development of gallstone disease (GSD) after bariatric surgery is a significant problem. The prophylactic effect of ursodeoxycholic acid (UDCA) preparations on the occurrence of cholelithiasis after gastric bypass and longitudinal gastrectomy has been studied. Aims: The aim of the st...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander V. Smirnov, Yuri V. Ivanov, Vladimir R. Stankevich, Valentin I. Sharobaro, Eugen A. Velichko
Formato:	article
Lenguaje:	RU
Publicado:	Eco-vector 2021
Materias:	gallstone disease cholelithiasis cholecystitis ursodeoxycholic acid bariatric surgery cholecystectomy gastric bypass longitudinal gastrectomy Medicine R
Acceso en línea:	https://doaj.org/article/799ff5f183584fbe9a66c8f49098ada7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:799ff5f183584fbe9a66c8f49098ada7
record_format	dspace
spelling	oai:doaj.org-article:799ff5f183584fbe9a66c8f49098ada72021-11-30T18:15:21ZUrsodeoxycholic acid for the prevention of gallstone disease after bariatric surgery2220-30952618-862710.17816/clinpract71457https://doaj.org/article/799ff5f183584fbe9a66c8f49098ada72021-07-01T00:00:00Zhttps://journals.eco-vector.com/clinpractice/article/viewFile/71457/pdfhttps://doaj.org/toc/2220-3095https://doaj.org/toc/2618-8627Background: The development of gallstone disease (GSD) after bariatric surgery is a significant problem. The prophylactic effect of ursodeoxycholic acid (UDCA) preparations on the occurrence of cholelithiasis after gastric bypass and longitudinal gastrectomy has been studied. Aims: The aim of the study was to evaluate the effectiveness of ursodeoxycholic acid preparations in the prevention of cholelithiasis in patients after bariatric surgery. Methods: The results of a year-long follow-up for 128 patients after bariatric surgery were analyzed. In 68 patients, the prophylaxis of the gallstone disease development was not performed. 60 patients took a daily 500 mg dose of UDCA orally. Results: Cholelithiasis had developed in 17 (25%) patients who did not undergo the prophylaxis of cholelithiasis. Of these, 10 (14.7%) underwent cholecystectomy. Among those patients who took UDCA drugs, stones in the gallbladder were found in 7 (11.6%), and only one patient (1.7%) required a surgical treatment. Conclusion: UDCA administration during the first year after bariatric surgery in the amount of 500 mg per day significantly reduces the likelihood of the de novo cholelithiasis development. The medical prophylaxis of gallstone disease should be included in the standards of bariatric patients' management.Alexander V. SmirnovYuri V. IvanovVladimir R. StankevichValentin I. SharobaroEugen A. VelichkoEco-vectorarticlegallstone diseasecholelithiasischolecystitisursodeoxycholic acidbariatric surgerycholecystectomygastric bypasslongitudinal gastrectomyMedicineRRUКлиническая практика , Vol 12, Iss 2, Pp 54-59 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	gallstone disease cholelithiasis cholecystitis ursodeoxycholic acid bariatric surgery cholecystectomy gastric bypass longitudinal gastrectomy Medicine R
spellingShingle	gallstone disease cholelithiasis cholecystitis ursodeoxycholic acid bariatric surgery cholecystectomy gastric bypass longitudinal gastrectomy Medicine R Alexander V. Smirnov Yuri V. Ivanov Vladimir R. Stankevich Valentin I. Sharobaro Eugen A. Velichko Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
description	Background: The development of gallstone disease (GSD) after bariatric surgery is a significant problem. The prophylactic effect of ursodeoxycholic acid (UDCA) preparations on the occurrence of cholelithiasis after gastric bypass and longitudinal gastrectomy has been studied. Aims: The aim of the study was to evaluate the effectiveness of ursodeoxycholic acid preparations in the prevention of cholelithiasis in patients after bariatric surgery. Methods: The results of a year-long follow-up for 128 patients after bariatric surgery were analyzed. In 68 patients, the prophylaxis of the gallstone disease development was not performed. 60 patients took a daily 500 mg dose of UDCA orally. Results: Cholelithiasis had developed in 17 (25%) patients who did not undergo the prophylaxis of cholelithiasis. Of these, 10 (14.7%) underwent cholecystectomy. Among those patients who took UDCA drugs, stones in the gallbladder were found in 7 (11.6%), and only one patient (1.7%) required a surgical treatment. Conclusion: UDCA administration during the first year after bariatric surgery in the amount of 500 mg per day significantly reduces the likelihood of the de novo cholelithiasis development. The medical prophylaxis of gallstone disease should be included in the standards of bariatric patients' management.
format	article
author	Alexander V. Smirnov Yuri V. Ivanov Vladimir R. Stankevich Valentin I. Sharobaro Eugen A. Velichko
author_facet	Alexander V. Smirnov Yuri V. Ivanov Vladimir R. Stankevich Valentin I. Sharobaro Eugen A. Velichko
author_sort	Alexander V. Smirnov
title	Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
title_short	Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
title_full	Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
title_fullStr	Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
title_full_unstemmed	Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
title_sort	ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery
publisher	Eco-vector
publishDate	2021
url	https://doaj.org/article/799ff5f183584fbe9a66c8f49098ada7
work_keys_str_mv	AT alexandervsmirnov ursodeoxycholicacidforthepreventionofgallstonediseaseafterbariatricsurgery AT yurivivanov ursodeoxycholicacidforthepreventionofgallstonediseaseafterbariatricsurgery AT vladimirrstankevich ursodeoxycholicacidforthepreventionofgallstonediseaseafterbariatricsurgery AT valentinisharobaro ursodeoxycholicacidforthepreventionofgallstonediseaseafterbariatricsurgery AT eugenavelichko ursodeoxycholicacidforthepreventionofgallstonediseaseafterbariatricsurgery
_version_	1718406388450852864

Ursodeoxycholic acid for the prevention of gallstone disease after bariatric surgery

Ejemplares similares